Elanco Animal Health (ELAN) CEO Jeffrey Simmons adds 22,000 shares

Rhea-AI Filing Summary

Elanco Animal Health Inc. President, CEO and Director Jeffrey N. Simmons reported buying 22,000 shares of Elanco common stock on December 11, 2025. The shares were purchased in multiple transactions at a weighted average price of $21.7498 per share, with individual trade prices ranging from $21.739 to $21.75.

After this transaction, Simmons beneficially owned 167,000 shares held indirectly through a revocable trust and 1,802,380 shares held directly. The direct holdings include 1 share acquired on April 30, 2025 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan.

Insider Trade Summary

Net Buyer: 22,000 shares

Net Buy 2 txns

Insider Simmons Jeffrey N

Role PRESIDENT, CEO AND DIRECTOR

Bought 22,000 shs ($478K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	22,000	$21.7498	$478K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 167,000 shares (Indirect, By Revocable Trust); Common Stock — 1,802,380 shares (Direct)

Footnotes (2)

1. F1. Reflects the weighted average price of 22,000 shares of common stock of Elanco Animal Health Inc. purchased by the reporting person in multiple transactions on December 11, 2025 with purchase prices ranging from $21.739 to $21.75 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
2. F2. Includes 1 share acquired on April 30, 2025 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 12/15/2025 - 04:41 PM Learn about SEC filing dates

FAQ

What insider stock transaction did Elanco (ELAN) disclose for Jeffrey N. Simmons?

Elanco Animal Health Inc. disclosed that President, CEO and Director Jeffrey N. Simmons purchased 22,000 shares of Elanco common stock on December 11, 2025.

At what price did Jeffrey N. Simmons buy Elanco (ELAN) shares?

The 22,000 Elanco shares were bought at a weighted average price of $21.7498 per share, with individual trades priced between $21.739 and $21.75 per share.

How many Elanco (ELAN) shares does Jeffrey N. Simmons own after this transaction?

Following the reported purchase, Jeffrey N. Simmons beneficially owned 167,000 shares of Elanco common stock indirectly through a revocable trust and 1,802,380 shares directly.

What is the role of Jeffrey N. Simmons at Elanco Animal Health Inc. (ELAN)?

Jeffrey N. Simmons is identified in the filing as President, CEO and Director of Elanco Animal Health Inc.

Does Jeffrey N. Simmons hold Elanco (ELAN) shares through a trust?

Yes. After the reported purchase, he held 167,000 shares of Elanco common stock indirectly through a revocable trust, in addition to his directly held shares.

What additional detail is provided about Jeffrey N. Simmons's direct Elanco (ELAN) holdings?

The filing notes that his direct ownership of 1,802,380 shares includes 1 share acquired on April 30, 2025 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simmons Jeffrey N

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CEO AND DIRECTOR

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/11/2025		P		22,000	A	$21.7498(1)	167,000	I	By Revocable Trust
Common Stock								1,802,380(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the weighted average price of 22,000 shares of common stock of Elanco Animal Health Inc. purchased by the reporting person in multiple transactions on December 11, 2025 with purchase prices ranging from $21.739 to $21.75 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

2. Includes 1 share acquired on April 30, 2025 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.